# US 2011/0257194 A1 · Substituted oxindol derivatives and medicaments containing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257194 A1
- Document ID: US20110257194A1
- Status: Published application
- Kind: A1
- Application number: 13/112,550
- Filed: 2011-05-20
- Published: 2011-10-20
- Earliest claimed: 2004-07-13
- Assignees: Abbott GmbH & Co. KG
- Inventors: Wilfried Lubisch; Thorsten Oost; Wolfgang Wernet; Liliane Unger; Wilfried Hornberger; Hérve Geneste; Andrea Hager-Wernet
- Web page: https://patentgrep.com/patent/US20110257194A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 209/34: in position 2
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel oxindole derivatives of the general formula (I), wherein the substitutes A, B, R1, R2 and R3 are as defined in Claim 1, and medicaments containing the same for the prophylaxis and/or treatment of vasopressin-dependent or oxytocin-dependent diseases.

## Claims

### Claim 1

Compound or compounds of the general formula (I),
wherein
A is C6-10-aryl, which can be substituted with a maximum of four residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)0-2—CN, CF3, OCF3, CONH2, CONH(C1-C4 alkyl), CON(C1-C4 alkyl)(C1-C4 alkyl), NHCHO, NHCONH2, N(C0-C4 alkylene)CONH2, N(C0-C4 alkylene)CONH(C1-C4 alkyl), NHCOCH3, NO2, (CH2)0-2—OH, O—C1-C6 alkyl, (CH2)0-2—O—C1-C4 alkyl, O—C0-C4 alkylene-phenyl, phenyl, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl,
B is an aromatic or partially aromatic monocyclic or bicyclic C6-10 that can be substituted with the residues R6, R7, R8 and/or R9, wherein R6, R7, R8 and R9 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, (CH2)0-2—CN, CF3, OCF3, CONH2, CONH(C1-C4 alkyl), CON(C1-C4 alkyl)(C1-C4 alkyl), NHCHO, N(C0-4 alkylene)CONH(C1-C4 alkyl), NHCOCH3, NO2, OH, O—C1-C4 alkyl, (CH2)0-2—O—(CH2)0-3—CH3, O—C0-C4 alkylene-phenyl, phenyl, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl.
R1 is hydrogen, C1-C6 alkyl, OH, O—(C1-C4 alkyl), N(C1-C4 alkyl)(C1-C4 alkyl), CN, CONH2, OCF3, CF3, Br, F, Cl, J, NO2, NHCHO, NHCO(C1-C4 alkyl) or NHCONH2,
R2 is hydrogen, C1-C4 alkyl, O—(C1-C4 alkyl), Cl or F,
R3 is a residue (W)—(X)—(Y)—Z, wherein
wherein Y can additionally be substituted with R10 and/or R11, wherein
R10 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,
OH, O—C1-C4 alkyl, O—C0-C4 alkylene-phenyl, NH2, NH(C1-C4 alkyl) or N(C1-C4 alkyl)(C1-C4 alkyl),
R11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, O—C1-C4 alkyl, O—C0-C4 alkylene-phenyl, NH2, NH(C1-C4 alkyl) or N(C1-C4 alkyl)(C1-C4 alkyl), and
Z is a residue selected from the group consisting of
wherein Z can additionally be substituted with R12 and/or R13, wherein
R12 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, O—C1-C4 alkyl, O—C0-C4 alkylene-phenyl, NH2, NH(C1-C4 alkyl) or N(C1-C4 alkyl)(C1-C4 alkyl),
R13 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, O(C1-C4 alkyl), O—C0-C4 alkylene-phenyl, NH2, NH(C1-C4 alkyl) or N(C1-C4 alkyl)(C1-C4 alkyl),
R14 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C0-C4 alkylene-phenyl, and their tautomeric, enantiomeric and/or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

### Claim 2 (depends on 1)

Compound or compounds according to claim 1, wherein A is a phenyl ring that can be substituted with a maximum of four residues R4 and B is a phenyl ring that can be substituted with the residues R6, R7, R8 and/or R9, wherein the residues R4, R6, R7, R8 and R9 shall have the meanings cited in claim 1,
and their tautomeric, enantiomeric and/or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

### Claim 3 (depends on 1)

Compound or compounds according to claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O—C1-C4 alkyl, (CH2)0—2—O—(CH2)0—2—CH3 ad C1-C6 alkyl,
B is a phenyl ring that can be substituted with the residues R6, R7, R8 and/or R9, wherein R6, R7, R8 and R9 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O—C1-C4 alkyl, (CH2)0-2—O—(CH2)0-2—CH3 and C1-C6 alkyl,
R1 is hydrogen, CN, F, Cl, C1-4 alkyl, OH or O—(C1-4 alkyl),
R2 is hydrogen,
R3 is a residue (W)—(X)—(Y)—Z, wherein
W is O, CH2NH, NHCH2, OCH2, CH2O or NH,
X is CO,
Y is a residue selected from the group consisting of
Z a residue selected from the group consisting of
wherein Z can additionally be substituted with R12 and I or R13, wherein
R12 is hydrogen or C1-C4 alkyl,
R13 is hydrogen or C1-C4 alkyl and wherein
R14 is hydrogen, C1-C4 alkyl, C2—Ca alkenyl or C2-C4 alkynyl,
and their tautomeric, enantiomeric and/or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

### Claim 4 (depends on 1)

Compound or compounds according to claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O—C1-C4 alkyl, (CH2)0-2—O—(CH2)0-2—CH3 and C1-C6 alkyl,
B is a phenyl ring that can be substituted with the residues R6 and/or R7 wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O—C1-C4 alkyl and C1-C6 alkyl,
R1 is hydrogen, F, Cl, CH3, CN, CH2CH3, OCH3 or OCH2CH3,
R2 is hydrogen,
R3 is a residue (W)—(X)—(Y)—Z, wherein
W is O, CH2 or NH,
X is CO,
Y is a residue selected from the group
Z is a residue selected from the group
wherein Z can be substituted with R12 and I or R13, wherein
R12 is hydrogen or C1-C4 alkyl,
R13 is hydrogen or C1-C4 alkyl and
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl,
and their tautomeric, enantiomeric and/or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

### Claim 5 (depends on 1)

Compound or compounds according to claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O—C1-C4 alkyl, (CH2)0-2—O—(CH2)0-2—CH3, and C1-C6 alkyl,
B is a phenyl ring that can be substituted with the residues R6 and/or R7, wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O—C1-C4 alkyl, and C1-C6 alkyl,
R1 is CI, CH3, CN, CH2CH3 or OCH3,
R2 is hydrogen,
R3 is a residue (W)—(X)—(Y)—Z, wherein
W is O, CH2, or NH,
X is CO,
Y is a residue
Z is a residue
wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl,
and their tautomeric, enantiomeric and/or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

### Claim 6 (depends on 1)

Compound or compounds according to claim 1, wherein
A is a phenyl ring that can be substituted with a maximum of two residues R4 that are selected independently of one another from the group consisting of hydrogen, chlorine, O—C1-C4 alkyl and C1-C4 alkyl,
B is a phenyl ring that is substituted with the residues R6 and/or R7, wherein R6 and R7 are selected independently of one another from the group consisting of hydrogen, fluorine, chlorine, O—C1-C4 alkyl, and C1-C6 alkyl,
R1 is hydrogen, Cl, CH3, CN, CH2CH3, OCH3 or OCH2CH3,
R2 is hydrogen,
R3 is a residue (W)—(X)—(Y)—Z, wherein
W is CH2, O or NH,
X is CO,
Y is a residue
and
Z is a residue
wherein
R14 is hydrogen, C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkynyl,
and their tautomeric, enantiomeric and/or diastereomeric forms, their prodrugs, as well as the physiologically compatible salts of the aforementioned compound or compounds.

### Claim 7 (depends on 1)

Medicaments containing at least one compound of claim 1 as well as, where applicable, customary pharmaceutical auxiliary agents.

### Claim 8 (depends on 1)

The method of at least one compound of claim 1 for the treatment and/or prophylaxis of vasopressin-dependent or oxytocin-dependent diseases.

### Claim 9 (depends on 1)

The method of at least one compound of claim 1 for the treatment and/or prophylaxis of at least one disease, selected from the group consisting of diabetes insipidus, nocturnal enuresis, incontinence and diseases in which coagulation disorders occur and/or for the delay of micturition.

### Claim 10 (depends on 1)

The method of at least one compound of claim 1 for the treatment and/or prophylaxis of at least one disease selected from the group consisting of hypertension, pulmonary hypertension, cardiac insufficiency, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, oedemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and peptic ulcer, emesis, recurrent emesis during chemotherapy and/or travel sickness.

### Claim 11 (depends on 1)

Method for the therapeutic and/or prophylactic treatment of a mammal that requires treatment, by administration of at least one compound of claim 1 for the treatment of diseases.

### Claim 12 (depends on 1)

The method of at least one compound of claim 1 for the treatment of affective disorders.

### Claim 13 (depends on 1)

The method of at least one compound of claim 1 for the treatment of anxiety disorders and/or stress-dependent anxiety disorders.

### Claim 14 (depends on 1)

The method of at least one compound of claim 1 for the treatment of memory disturbances and/or Alzheimer disease.

### Claim 15 (depends on 1)

The method of at least one compound of claim 1 for the treatment of psychoses and/or psychotic disorders.

### Claim 16 (depends on 1)

The method of at least one compound of claim 1 for the treatment of Cushing Syndrome.

### Claim 17 (depends on 1)

The method of at least one compound of claim 1 for the treatment of sleep disorders.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

Method for the production of a compound according to the general formula (I)
wherein the residues R1, R2, R3, A and B have the meaning mentioned in in claim 1, characterized in that, according to the method variant (A), isatin or isatin derivative, known per se, which is substituted with the residues R1 and R2, is reacted by the introduction of the residue A into the 3-position while maintaining the corresponding 3-hydroxy-oxindole-derivatives, followed by the introduction of the B—SO2 residue at the ring nitrogen and exchange of the residue R3 with the 3-hydroxy group or another suitable nucleofuge according to procedures known per se
or, according to method variant (B), the isatin or isatin derivative, known per se, which is substituted with the residues R1 and R2, is reacted first by the introduction of the residue B—SO2 at the ring nitrogen and then by introduction of the residue A into the 3-position while maintaining the corresponding 3-hydroxy-oxindole derivatives, followed by the exchange of the residue R3 with the 3-hydroxy group or another suitable nucleofuge according to procedures known per se.
